Treatments for cancer impose substantial burden and morbidity but net survival benefit of different strategies is often small and virtually always uncertain. Thus, clinicians may do more harm than good if treatment is too aggressive. There are a number of management strategies for breast cancer aimed at reducing unnecessary morbidity and burden on patients with favorable disease. A key barrier to advancing these initiatives is the need for a better understanding of the challenges of individualizing cancer care The goal of this program is to improve population health by helping clinicians and their patients address the challenges of individualizing treatment of breast cancer for patients with favorable prognosis. Objective 1: To examine the challenges of individualizing treatment for women with breast cancer. Two projects will each undertake an observational study of patients newly diagnosed with breast cancer (including their attending clinicians) who were reported to the SEER registries of Georgia and New Jersey during an 18 month period to examine patient and clinician factors associated with key evaluative tests, treatments, and patient appraisal of decision quality. Project 1 will focus on challenges for surgeons and their patients with regard to locoregional therapy. Project 2 will focus on challenges for medical oncologists and their patients with regard to systemic therapy. Objective 2: To improve treatment decision quality. Project 3 will perform a randomized controlled trial of a practice based online decision tool for patients newly diagnosed with breast cancer in the Detroit and Atlanta SEER regions intended to improve decision quality. Objective 3: To accelerate the dissemination of SEER-based research findings by implementing and evaluating a tailored online portal aimed at all surgeons and medical oncologists who treated the patient samples in P1 and P2 to evaluate whether our research findings can more directly and promptly inform clinicians knowledge and attitudes about individualizing treatment. Objective 4: To advance methods in SEER population translational research focused on quality of cancer care. We propose four shared resource cores that will support program project activities, advance innovative methods in oncology population sciences, and advance team mission and long-term strategic planning.

Public Health Relevance

Results from the proposed program will improve public health by addressing the challenges of individualizing cancer care. This includes evaluating a compelling conceptual framework salient to patients and their physicians, informing the challenges of communication in the exam room, improving breast cancer treatment decision-making, and advancing innovative methods in population-based oncology outcomes research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA163233-01A1
Application #
8340091
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M1))
Program Officer
Arora, Neeraj K
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$2,943,844
Indirect Cost
$738,798
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Katz, Steven J; Hawley, Sarah T; Hamilton, Ann S et al. (2018) Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer. JAMA Surg 153:29-36
Lee, Kamaria L; Janz, Nancy K; Zikmund-Fisher, Brian J et al. (2018) What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Med Decis Making 38:95-106
Morrow, Monica; Jagsi, Reshma; McLeod, M Chandler et al. (2018) Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer. JAMA Oncol 4:1511-1516
Radhakrishnan, Archana; Chandler McLeod, M; Hamilton, Ann S et al. (2018) Preferences for Physician Roles in Follow-up Care During Survivorship: Do Patients, Primary Care Providers, and Oncologists Agree? J Gen Intern Med :
Jagsi, Reshma; Ward, Kevin C; Abrahamse, Paul H et al. (2018) Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer 124:3668-3676
Kurian, Allison W; Ward, Kevin C; Hamilton, Ann S et al. (2018) Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol 4:1066-1072
Resnicow, Ken; Patel, Minal R; Mcleod, M Chandler et al. (2018) Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty. Breast Cancer Res Treat :
Katz, Steven J; Bondarenko, Irina; Ward, Kevin C et al. (2018) Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surg 153:909-916
Morrow, Monica; Abrahamse, Paul; Katz, Steven J (2018) Trend Analysis on Reoperation After Lumpectomy for Breast Cancer-Reply. JAMA Oncol 4:747
Gornick, Michele C; Kurian, Allison W; An, Lawrence C et al. (2018) Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. Cancer 124:4000-4009

Showing the most recent 10 out of 47 publications